For decades, software has taught us an important lesson:
Don't wait for errors at runtime if you can prevent them at compile time.
Yet medication safety still largely follows the opposite philosophy.
A clinician builds a medication regimen.
Then a system asks:
“Are there any interactions?”
If there are, it generates alerts.
The clinician reviews them.
The workflow continues.
This is basically runtime error detection for pharmacology.
What if we changed the abstraction completely?
What if a medication regimen were something we compiled?
From Interaction Checker to Regimen Compiler
The conventional model looks like this:
Drug A + Drug B
↓
Interaction Database
↓
Potential Interaction
↓
Alert
↓
Human Review
The problem is not simply that there are too many alerts.
The deeper problem is that the system is solving the wrong problem.
Instead of asking:
“Does this regimen contain an interaction?”
we should ask:
“Which candidate regimens satisfy the patient's therapeutic and pharmacological constraints?”
That is a fundamentally different computational problem.
Regimen-as-Program
Imagine representing a medication regimen as a program.
Regimen(
drugs,
doses,
timing,
duration,
patient_state,
therapeutic_goals
)
Each medication carries a machine-readable pharmacological signature:
Drug {
PK_signature
PD_signature
renal_load
hepatic_load
bleeding_effect
QT_effect
CNS_effect
serotonin_effect
enzyme_interactions
transporter_interactions
temporal_constraints
dose_constraints
}
The patient becomes another computational object:
Patient {
renal_capacity
hepatic_capacity
age
comorbidities
current_exposures
genetic_constraints
physiological_reserve
uncertainty
}
Now the problem becomes:
Therapeutic Goals
│
▼
Candidate Generation
│
▼
Pharmacological Types
│
▼
Constraint Solver
│
▼
Temporal Verification
│
▼
Evidence Verification
│
▼
Candidate Regimens
│
▼
Human Review
The system doesn't merely detect bad combinations.
It constructs candidates that satisfy an explicit safety specification.
The "Safe Corridor"
Think of all possible medication regimens as a gigantic multidimensional space.
Each dimension represents something different:
- medication selection
- dose
- timing
- duration
- metabolism
- renal clearance
- hepatic function
- pharmacodynamic effects
- comorbidities
- genetics
- therapeutic objectives
- formulary constraints
- uncertainty
Most of this space may be clinically irrelevant, inappropriate, or unsafe.
The compiler searches for a constrained region:
REGIMEN SPACE
┌─────────────────────────┐
│ │
│ unsafe │
│ │
│ ┌─────────┐ │
│ │ │ │
│ │ SAFE │ │
│ │CORRIDOR │ │
│ │ │ │
│ └─────────┘ │
│ │
└─────────────────────────┘
The goal isn't to produce an infinite list of warnings.
The goal is to navigate the patient toward the feasible region.
But There Is a Bigger Problem
Drug interactions aren't static.
Consider:
Drug A @ 08:00
Drug B @ 09:00
Drug C @ 20:00
Drug D @ every 48 hours
Compare that with:
Drug A
Drug B
Drug C
Drug D
all administered together
The medication list is identical.
The regimen is not.
This suggests that conventional pairwise interaction models are incomplete.
We need a Temporal Interaction Graph.
Instead of:
A ↔ B
we model:
A(t1)
│
├── exposure
│
B(t2)
│
├── metabolic effect
│
C(t3)
│
└── physiological state
Interaction becomes a function:
I = f(
drugs,
dose,
timing,
duration,
patient_state,
exposure
)
Now we're no longer looking at a static database lookup.
We're modeling a dynamic system.
The Compiler Should Have a Type System
Here's where the analogy gets interesting.
In programming:
string + integer
can produce a type error.
In pharmacology, combinations can violate constraints such as:
excessive bleeding risk
+
renal clearance limitation
+
sedation burden
+
QT liability
+
enzyme inhibition
So imagine a pharmacological type system:
Drug X
↓
[Renal-sensitive]
[QT-active]
[CNS-depressant]
[Enzyme-substrate]
The compiler evaluates composition:
Drug X
+
Drug Y
+
Patient State
+
Schedule
↓
TYPE CHECK
↓
PASS / FAIL / UNCERTAIN
And uncertainty is important.
A medical safety system should not pretend that incomplete evidence is equivalent to safety.
Therefore:
PASS
FAIL
ABSTAIN
may be more appropriate than:
SAFE
UNSAFE
Enter the Counterfactual Engine
Here's another layer.
Suppose a candidate regimen violates a constraint.
A conventional checker says:
Interaction detected.
A compiler could ask:
What is the smallest change that moves this regimen back toward the feasible region?
For example:
Original Regimen
│
├── Change dose
│
├── Change timing
│
├── Substitute medication
│
├── Remove medication
│
└── Increase monitoring
│
▼
Counterfactual Regimens
│
▼
Constraint Analysis
This produces something much more useful than a warning list:
A Regimen Sensitivity Map
It tells the clinician which variables are driving the constraint violation.
Not:
“Something is wrong.”
But:
“This region of the regimen is sensitive to these variables.”
That is a completely different interaction model.
Where Does AI Fit?
Not where people usually put it.
I would not put an LLM in charge of deciding whether a drug combination is safe.
That would be the wrong abstraction.
Instead:
Deterministic layer
Handles:
- pharmacological constraints
- dose rules
- renal/hepatic adjustments
- temporal constraints
- interaction rules
- evidence provenance
- formal verification
Optimization layer
Handles:
- candidate generation
- multi-objective optimization
- formulary constraints
- cost
- availability
- regimen complexity
LLM layer
Handles:
- explanation
- evidence summarization
- clinician questions
- uncertainty communication
- human-readable reasoning
In other words:
LLM
│
Explanation
│
┌────────┴────────┐
│ │
Optimization Verification
│ │
└────────┬────────┘
│
Pharmacological
Constraint
Engine
The LLM explains the compiler.
It should not secretly become the compiler.
This Changes the Product Category
Traditional system:
Drug Interaction Checker
New abstraction:
Medication Regimen Compiler
Traditional question:
“Is A interacting with B?”
New question:
“Which regimens satisfy this patient's therapeutic objectives and explicit pharmacological constraints?”
Traditional output:
⚠️ Interaction
⚠️ Interaction
⚠️ Interaction
⚠️ Interaction
New output:
Candidate Regimen 01
Candidate Regimen 02
Candidate Regimen 03
Constraint status
Evidence provenance
Uncertainty
Trade-offs
The interface changes because the underlying computational problem changed.
And This Is Where It Gets Really Interesting
Once medication regimens become computational objects, we can potentially introduce:
Regimen version control
Regimen v1
↓
Regimen v2
↓
Regimen v3
Every modification becomes auditable.
Evidence provenance
Every constraint can carry:
source
version
date
evidence level
confidence
Local execution
Sensitive patient information can remain inside the clinical environment while evidence metadata is updated separately.
Learning loops
With appropriate governance, real-world outcomes could eventually inform which constraints deserve recalibration.
But this must not become:
“The AI learned that this combination is safe.”
The correct principle is:
Observed outcomes can improve the model; they do not replace clinical evidence or validation.
The Hardest Engineering Problem
Ironically, generating candidates may not be the hardest part.
Proving why a candidate should be trusted is harder.
A production system would need:
- deterministic rule execution
- evidence versioning
- provenance
- audit logs
- uncertainty representation
- reproducibility
- conflict resolution between sources
- temporal modeling
- human override
- abstention
- rigorous validation
And above all:
No silent clinical decisions.
The compiler should be designed as a decision-support system, not an autonomous prescriber.
The Bigger Idea
This architecture is not really about drug interactions.
Drug interactions are simply the first use case.
The deeper abstraction is:
Constraint-aware compilation of complex therapeutic plans.
The same architecture could eventually apply to other domains where multiple interventions interact with a dynamic human system.
The important conceptual shift is:
Detect → Alert → Correct
becoming:
Specify → Compile → Verify → Review
That is the difference between building a better warning system and inventing a new computational model for medication safety.
From Runtime Errors to Design-Time Safety
Software engineering spent decades moving from:
“Find the bug after execution”
toward:
“Make invalid states harder to represent.”
Medication safety has an opportunity to explore a similar transition.
Not:
“Which drugs interact?”
But:
“Which therapeutic programs are admissible under the patient's constraints?”
Not:
“How many alerts can we generate?”
But:
“How much unsafe search space can we eliminate before clinical execution?”
And perhaps the most important question:
What if medication safety is not fundamentally an alerting problem at all—but a compilation problem?
That is the hypothesis worth testing.
A possible research program
The first prototype does not need thousands of diseases or millions of medications.
Start narrow.
For example:
Population:
Older adults with polypharmacy
Domain:
Anticoagulation + cardiovascular + pain management
Inputs:
Medications
Dose
Timing
Renal function
Major comorbidities
Baseline:
Conventional interaction checker
Experimental system:
Regimen Compiler
Then measure:
- clinically relevant interaction coverage
- false-alert reduction
- constraint violations
- regimen complexity
- clinician review time
- abstention quality
- evidence traceability
- agreement with validated references
The central research question becomes:
Can design-time constrained regimen synthesis reduce clinically relevant medication-safety failures compared with conventional post-hoc interaction checking?
That is a falsifiable question.
And that's where an interesting idea stops being a pitch—
and starts becoming a research program.
The future of medication safety may not be a smarter warning system.
It may be a compiler.
created by Seyed Alireza Alhosseini Almodarresieh
Top comments (0)